[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatic-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatic-transplantation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100612511","diagnosis-and-quantification-of-hepatic-steatosis-using-near-infrared-spectroscopy-100612511",false,"NCT07254533","Diagnosis and Quantification of Hepatic Steatosis Using Near-infrared Spectroscopy","STEATO-NIR","Inclusion Criteria:\n\nLiver grafts:\n\n* Men or women aged 18 and over\n* All donors accepted by the MA4FC procurement team, including brain-dead donors and Maastricht 3 donors, even if placed on a perfusion machine\n* Donors whose families have received information about the study and have not expressed any opposition\n\nSurgical specimens (hepatectomy):\n\n* Men or women aged 18 years and older\n* Subjects who have undergone surgery for any indication of hepatectomy\n* Affiliated with social security,\n* Having received information about the study and not having expressed opposition\n\nExclusion Criteria:\n\nLiver grafts:\n\n* Donors whose liver will be subject to a SPLIT procedure\n* Donors for whom there is a medical-legal obstacle\n* Donors whose family or loved ones oppose scientific sampling: The hospital coordination team will consult the national refusal register and question loved ones to determine whether the deceased would have opposed sampling. If the donor and\u002For family oppose scientific sampling, then sampling will not be performed.\n\nSurgical specimens (hepatectomy):\n\n* Subjects covered by Articles L1121-5 to 1121-8 of the Public Health Code (minors, adults under guardianship or curatorship, patients deprived of their liberty, pregnant or breastfeeding women),\n* Subjects who do not understand the French language","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"NA","In liver transplantation, the main problem is the shortage of grafts due to the small pool of donors. In order to increase the number of donors, grafts are increasingly being taken from older donors, known as 'expanded criteria' donors, who have liver steatosis lesions. Currently, expanded criteria donors account for 75% of liver transplants, whereas in 2009 they accounted for less than 30% of liver transplants.\n\nSteatosis and its progression Non-alcoholic steatohepatitis (NASH) is an emerging disease in industrialised countries due to obesity, and corresponds to the accumulation of intracytoplasmic triglycerides.\n\nSteatosis is diagnosed when this fat content represents more than 5% of the total liver mass. There are two types of steatosis: microvesicular steatosis and macrovacuolar steatosis, defined by the presence of lipid droplets larger than the nucleus with a nucleus displaced to the periphery. Macrovacuolar steatosis is responsible for impaired liver function if it is present in ≥30% of hepatocytes. It is a factor in poor prognosis for liver transplants, with reduced graft and recipient survival and an increase in early graft dysfunction after liver transplantation. The quantification of hepatic steatosis is based on the pathological analysis of a liver biopsy, which is currently the gold standard.\n\nThis technique has disadvantages: it is an invasive method, requiring an experienced pathologist, and presents inter-individual variability in the assessment and quantification of steatosis.\n\nIt is therefore essential to develop new non-invasive diagnostic tools that can identify the presence of steatosis \\> 5% and ≥ 30%. Several non-invasive techniques for diagnosing steatosis have been studied: Fibroscan, CT scan, MRI, but none of those studied previously allow for the accurate quantification of hepatic steatosis, particularly macrovacuolar steatosis, with instant results.",[26,27],"Hepatic Transplantation","Steatohepatitis","NOT_YET_RECRUITING","2025-11-25",{"date":31,"type":32},"2025-11-28","ACTUAL",{"date":34,"type":20},"2026-01",{"date":36,"type":20},"2027-01",{"name":38,"class":39},"Assistance Publique Hopitaux De Marseille","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100586149","impact-of-nutritional-management-on-the-frailty-of-patients-waiting-for-liver-transplantation-via-the-lfi-tool-100586149","NCT06911619","Impact of Nutritional Management on the Frailty of Patients Waiting for Liver Transplantation (Via the LFI Tool)","LFI-PATH","Inclusion Criteria:\n\n* Patient aged ≥ 18 years\n* Patient registered on the waiting list for Hepatic Transplantation in the Transplantation center of the Croix Rousse Hospital (GHN), Hospices Civils de Lyon\n* Dated and signed an informed consent\n* Affiliated to a social security scheme or beneficiary of a similar scheme\n\nExclusion Criteria:\n\n* Patient hospitalized in intensive care\n* Patient with initial LFI test result \\\u003C to 3.2, that is considered as \"robust\".\n* Patient unable to perform LFI exercises (chronic or acute motor disability in lower or upper limbs)\n* Pregnant, parturient or lactating women\n* Persons deprived of liberty by a judicial or administrative decision\n* Persons under psychiatric care\n* Persons admitted to a health or social institution for purposes other than research\n* Adults subject to a legal protection measure (guardianship, curatorship)\n* Inability to understand protocol information\n* Subject participating in another interventional research including an ongoing exclusion period at inclusion",{"count":49,"type":20},210,[23],"Cirrhosis is a major public health issue responsible for about 15000 deaths each year. Liver transplantation (LT) remains the only curative treatment for decompensated cirrhosis. Decompensated cirrhotic patients awaiting LT are malnourished, sarcopenic and fragile. The evaluation of the nutritional status of these patients is complex because the anthropometric data that define undernutrition (weight variation, BMI) are often compromised by the presence of edema and ascites related to liver disease. It therefore seems appropriate to focus on the fragility and sarcopenia of the cirrhotic patient as a reflection of the nutritional status. In 2017, the American team of Lai et al. validated a Liver fraily index (LFI) score of frailty specific to cirrhotic patients waiting for LT. The LFI is composed of three simple physical tests (Grip test, chair lift test, and balance tests) performed at the patient's bedside, which results in a quantitative and reproducible frailty score. Frailty while waiting for LT is associated with an increase in mortality on the waiting list, independently of the MELD (Model for End stage Liver disease) score, which is a reflection of liver severity. About half of the patients who are candidates for LT will present an aggravation of their frailty while waiting for LT. To date, no study has reported the results of a nutritional intervention on the evolution of fragility in patients awaiting LT. The objective of our study is to evaluate the impact of a nutritional management and follow-up by a dietitian specialized in hepatology on the fragility of patients waiting for LT. This is a monocentric study, randomized in two parallel groups (an intervention group with nutritional follow-ups by a trained dietitian and a control group with follow-up by the reference hepatologist without specific dietary management by a dietician) in open. All patients enrolled on the LT list with an LFI \\> 3.2 (pre-frail and frail state) will be included in the study. It is planned to include 210 patients over a period of 24 months. The LFI will be measured for all patients (control group + intervention group) at 3 and 6 months, as part of their follow-up in the LT center. This study will also make it possible to correlate frailty with other parameters (severity of liver disease, access to LT).",[53,54,26,55],"Fragility","Cirrhosis","Undernutrition",[57,26,54],"nutrition","RECRUITING","2025-07-01",{"date":61,"type":32},"2025-07-04",{"date":63,"type":32},"2025-06-30",{"date":65,"type":20},"2027-12-30",{"name":67,"class":39},"Hospices Civils de Lyon",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":40},"100571230","tissue-analysis-of-liver-grafts-as-a-predictor-of-transplant-outcome-100571230","NCT06717542","Tissue Analysis of Liver Grafts as a Predictor of Transplant Outcome.","Tissue Analysis (Histological, Ultrastructural and Molecular) of Liver Grafts as a Predictor of Transplant Outcome.","Inclusion Criteria:\n\n* For Donors:\n\nAvailability of enough tissue for histological, immunohistochemical and RT-PCR analysis.\n\n* HOPE performed on the liver graft prior to transplantation.\n* For Recipients:\n* Availability of enough tissue for histological, immunohistochemical and RT-PCR analysis.\n* Age greater than\u002Fequal to 18 years.\n\nExclusion Criteria:\n\n* None",{"count":76,"type":20},200,[23],"Despite the good clinical results in terms of outcome with the application of HOPE prior to liver transplantation, very little is still known about the phenotypic and molecular changes that occur during perfusion\u002Fpreservation during HOPE, particularly with regard to endothelial trophism and activation. Delving into these aspects would be very useful to allow personalised perfusion treatments in the future, thus improving the outcome of transplantation.",[26,80],"Rejection; Transplant, Liver",[82,83],"Transplant","Liver","2024-12-01",{"date":86,"type":32},"2024-12-05",{"date":88,"type":32},"2023-01-17",{"date":90,"type":20},"2028-01",{"name":92,"class":39},"IRCCS Azienda Ospedaliero-Universitaria di Bologna"]